Guanfacine Extended-release for Adolescents With Cannabis Use
ConditionCannabis Use Disorder
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age12-25
SponsorOrygen
About this trial
A randomized controlled trial to assess the efficacy of extended-release guanfacine to reduce cannabis use frequency in young people with cannabis use disorder following a period of monitored abstinence.
Eligibility criteria
Qualifiers
12-25 years of age (inclusive) at consent;
Seeking treatment for cannabis use;
DSM-5 Cannabis Use Disorder, mild, moderate or severe;
Self-reported cannabis use on average at least 5 days/week during the 28 days prior to screening with a THC positive urine drug screen on the day of screening; and
Disqualifiers
DSM-5 substance use disorder (moderate or severe) except cannabis or nicotine;
Any unstable medical, psychiatric or neurological condition or medical contraindicating study participation;
Diagnosis of a psychotic or bipolar illness;
Acute suicidality as assessed by clinician;
Trial design
Treatments tested in this trial
- Guanfacine Extended Release Oral Tablet
- Residential withdrawal
- Engagement with alcohol and other drug services
- Placebo
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov